- |||||||||| levetiracetam / Generic mfg.
Journal: Utility of monitoring the serum levetiracetam concentration for intraoperative seizure control during awake craniotomy. (Pubmed Central) - Jul 10, 2021
Levetiracetam was superior to phenytoin in terms of the correlation between the serum concentration and the dose adjusted for BSA and eGFR (correlation coefficient, 0.49 vs 0.21). Furthermore, the serum levetiracetam concentration in patients with intraoperative seizures was below the 95% confidence interval (CI) of the regression line whereas the serum phenytoin concentration of two patients with seizures was within the 95% CI, indicating that evaluating the serum levetiracetam concentration against the BSA and eGFR-adjusted dosage may be useful in preventing intraoperative seizures during awake craniotomy by allowing prediction of the seizure risk and enabling more accurate dosage calibration.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. (Pubmed Central) - Jul 8, 2021
We review the anion CA inhibitors (CAIs) in the more general context of drug design studies and the discovery of a large number of inhibitor classes and inhibition mechanisms, including zinc binders (sulphonamides and isosteres, dithiocabamates and isosteres, thiols, selenols, benzoxaboroles, ninhydrins, etc.); inhibitors anchoring to the zinc-coordinated water molecule (phenols, polyamines, sulfocoumarins, thioxocoumarins, catechols); CAIs occluding the entrance to the active site (coumarins and derivatives, lacosamide), as well as compounds that bind outside the active site. All these new chemotypes integrated with a general procedure for obtaining isoform-selective compounds (the tail approach) has resulted, through the guidance of rigorous X-ray crystallography experiments, in the development of highly selective CAIs for all human CA isoforms with many pharmacological applications.
- |||||||||| gabapentin / Generic mfg., carbamazepine / Generic mfg.
Clinical, Review, Journal: Which treatment strategy in patients with epilepsy with focal seizures uncontrolled by the first anti-seizure medication? (Pubmed Central) - Jul 2, 2021
Carbamazepine (CBZ) has negative pharmacokinetic interactions with several ASMs and should not be combined with other SCBs; it could be effectively and safely combined with gabapentin (GBP) and LEV. Valproic acid has enzyme inhibiting properties and can be cautiously used with SCBs; its combination with TPM or zonisamide (ZNS) may be associated with higher toxicity.
- |||||||||| desloratadine / Generic mfg.
Clinical, Journal: Epileptic convulsions probably induced by desloratadine: a case report. (Pubmed Central) - Jun 30, 2021
At the follow-up, his father reported that the boy's memory was not as good as it had been previously. The convulsions continued after the withdrawal of desloratadine; therefore, the pathological mechanism of convulsion and the treatment plan need further research.
- |||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: An uncommon case of nonconvulsive status epilepticus successfully treated with enteral Brivaracetam. (Pubmed Central) - Jun 30, 2021
The administration of new antiepileptic drugs (AEDs) such as BRV may result in significant clinical improvement in refractory cases of status epilepticus. The enteral administration of AEDs via NGT should always be considered for refractory cases of status epilepticus when standard iv treatment has failed or is not possible.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Efficacy and safety of lacosamide in the treatment of status epilepticus in a patient with comorbidities. (Pubmed Central) - Jun 30, 2021
EEG then showed focal slow waves mixed to interictal epileptiform discharges over the left fronto-temporal regions. The patient was then discharged home with an oral lacosamide treatment and at 3 months she was seizure-free. Our case report confirms the efficacy of lacosamide in status epilepticus, highlighting its safety and tolerability in an elderly and fragile patient with multiple comorbidities and drug therapy.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Preclinical, Journal: Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice. (Pubmed Central) - Jun 26, 2021
No adverse effects associated with triple ASM combinations, containing LCM and second-generation ASMs were observed in mice; (4) The combination of LCM + TPM + PGB was the most beneficial combination among the tested in this study, offering synergistic suppression of tonic-clonic seizures in mice subjected to the MES model. Both the isobolographic analysis and polygonogram method can be recommended for experimental epileptology when classifying interactions among the ASMs.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo, edonerpic (T-817MA) / Fujifilm Holdings
Journal: Druggability of CRMP2 for neurodegenerative diseases. (Pubmed Central) - Jun 22, 2021
These potential therapeutics include CRMP2-based peptides that inhibit protein-protein interactions and small-molecule compounds. Capitalizing on the availability of structural information, we identify druggable pockets on CRMP2 and predict binding modes for five known CRMP2-targeting compounds, setting the stage for optimization and de novo drug discovery targeting this multifunctional protein.
- |||||||||| carbamazepine / Generic mfg.
Review, Journal: Tics induced by antiepileptic drugs: a pragmatic review. (Pubmed Central) - Jun 22, 2021
Multiple AEDs with different modes of action can induce tic disorders, including newer AEDs. The cause is therefore unlikely to be an alteration to a single neurotransmitter, but rather an imbalance of networks, influenced further by individual factors.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Is intranasal administration an opportunity for direct brain delivery of lacosamide? (Pubmed Central) - Jun 22, 2021
Nevertheless, attained drug concentrations were lower than those tested in vitro in the Calu-3 cell line (1-100 µM), indicating that adverse effects are unlikely to occur in vivo. Hence, it seems that the proposed IN route has potential to be a suitable and valuable strategy for the brain delivery of lacosamide in emergency conditions and for the chronic treatment of epilepsy and other neurological diseases.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. (Pubmed Central) - Jun 22, 2021
Altogether, these assays demonstrated that the impact of BCRP on the delivery of zonisamide to the brain is lower after intranasal administration, probably due to direct nose-to-brain transport. Therefore, the intranasal administration of AEDs may be a relevant strategy to avoid the impact of efflux transporters at the BBB and the development of drug resistance.
- |||||||||| carbamazepine / Generic mfg.
Journal: HPLC method for the determination of antiepileptic drugs in human saliva and its application in therapeutic drug monitoring. (Pubmed Central) - Jun 22, 2021
Statistically significant correlations were observed (p < 0.05) for carbamazepine (r = 0.6887; r = 0.8299), carbamazepine-10,11-epoxide (r = 0.8633; r = 0.9291), S-licarbazepine (r = 0.5266; r = 0.7257) and levetiracetam (r = 0.7103; r = 0.8428). Our data support that this method can be used in TDM of AEDs using human saliva samples, constituting a new approach to establish individual therapeutic ranges and assess patient's adherence to treatment.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Review, Journal: Lacosamide add-on therapy for focal epilepsy. (Pubmed Central) - Jun 22, 2021
Higher doses of lacosamide may be associated with higher rates of adverse events and treatment withdrawal. Additional evidence is required assessing the use of lacosamide in children and on longer-term efficacy and tolerability.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo, Nucynta (tapentadol) / Collegium Pharma, Grunenthal
Biomarker, Clinical, Journal: IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG). (Pubmed Central) - Jun 22, 2021
For these reasons, IMI2-PainCare-BioPain-RCT3 hypothesizes that EEG-derived measures can serve as biomarkers of target engagement of analgesic drugs for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis. (Pubmed Central) - Jun 16, 2021
This case illustrates the need for careful follow-up of the electrocardiogram and the complete blood cell counts when initiating LCM. Moreover, it should be noticed that various side effects may occur simultaneously in the early period of LCM use, even for a short time and at low dosages.
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Glioblastoma (Pubmed Central) - Jun 8, 2021
In this chapter, I describe the overview of the multidisciplinary treatments of glioblastoma. I also describe the future perspectives.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Preclinical, Journal: Neuroprotective Effects of Lacosamide and Memantine on Hyperoxic Brain Injury in Rats. (Pubmed Central) - Jun 4, 2021
This study demonstrates that neuron death and apoptosis in newborn rat brains after hyperoxia is reduced upon memantine treatment. This is the first study to show the effects of memantine and lacosamide on hyperoxia-induced damage in neonatal rat brains.
- |||||||||| lacosamide / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers (clinicaltrials.gov) - Jun 3, 2021
P1, N=66, Completed,
This is the first study to show the effects of memantine and lacosamide on hyperoxia-induced damage in neonatal rat brains. Suspended --> Completed | N=28 --> 66 | Trial completion date: Mar 2021 --> Aug 2020 | Trial primary completion date: Mar 2021 --> Aug 2020
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Ictal visual hallucinations as a manifestation of hyperglycaemia (Room Istanbul) - May 30, 2021 - Abstract #EAN2021EAN_2168;
Hiperglycaemic states are sufficient conditions for development of acute symptomatic occipital seizures and typical MRI changes. During the period of uncontrolled glycaemia, visual phenomena can change over time, be refractory to antiepileptic drugs, and revert with correction of the metabolic insult.
- |||||||||| pregabalin / Generic mfg.
[VIRTUAL] Comparative efficacy and safety of anti- epileptic drugs in paediatric populations: A network meta-analysis (CBW Room) - May 30, 2021 - Abstract #EAN2021EAN_1484;
In DSA, perampanel 8mg/d was as effective as brivaracetam 100mg/d (relative risk [RR]: 0.97; 95% credible interval [CrI]: 0.75–1.28), lacosamide 300mg/d (RR: 1.11; CrI: 0.78–1.66) and pregabalin 300mg/d (RR: 0.78; CrI: 0.58– 1.14) and more effective than eslicarbazepine 200mg/d (RR: 1.66; CrI: 1.06, 2.85) in achieving 50% seizure reduction. Perampanel has similar efficacy and safety as other third-generation AEDs and greater 50% and 75% seizure reduction rates than eslicarbazepine, at medium doses.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo, Fycompa (perampanel) / Eisai
[VIRTUAL] Refractory opercular myoclonic-anarthric status epilepticus in coexistence with ANTI- SOX1 antibodies (CBW Room) - May 30, 2021 - Abstract #EAN2021EAN_1482;
A variable combination of antiepileptic drugs including lacosamide,phenytoin and finally perampanel was administered with partial response. OMASE as a clinical phenotype of NORSE is a rare neurological disorder Screening for possible autoimmune etiology is important in order to provide accurate diagnosis and the appropriate therapeutic plan.
- |||||||||| pregabalin / Generic mfg., gabapentin / Generic mfg., carbamazepine / Generic mfg.
Clinical, Review, Journal: Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy. (Pubmed Central) - May 29, 2021
There is limited data for cannabidiol, clobazam, eslicarbazepine acetate, ethosuximide, rufinamide, vigabatrin and zonisamide, although the available evidence suggests these drugs are not associated with severe cognitive impairment. There was too little information to reach conclusions about the effects of brivaracetam, felbamate, gabapentin, pregabalin, retigabine, stiripentol or tiagabine.
- |||||||||| gabapentin / Generic mfg., carbamazepine / Generic mfg.
Clinical, Review, Journal: Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy. (Pubmed Central) - May 25, 2021
Carbamazepine clearance remains unchanged during pregnancy...Monitoring of clobazam, N-desmethylclobazam, gabapentin, lacosamide, perampanel, and zonisamide during and after pregnancy should be considered...If that is impossible, monitoring of both total and unbound valproate is recommended. More research is needed on the large number of unclear pregnancy-related effects on the pharmacokinetics of antiepileptic drugs.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Preclinical, Journal: Effects of Lacosamide Treatment on Epileptogenesis, Neuronal Damage and Behavioral Comorbidities in a Rat Model of Temporal Lobe Epilepsy. (Pubmed Central) - May 25, 2021
Lacosamide treatment after SE mitigated the increased levels of IL-1β and TNF-α in the hippocampus and exerted strong neuroprotection both in the dorsal and ventral hippocampus, basolateral amygdala, and partially in the piriform cortex. Our results suggest that the antioxidant, anti-inflammatory, and neuroprotective activity of LCM is an important prerequisite for its anticonvulsant and beneficial effects on SE-induced behavioral comorbidities.
- |||||||||| carbamazepine / Generic mfg.
Clinical, Observational data, Retrospective data, Journal: Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohort. (Pubmed Central) - May 20, 2021
Our results suggest that the antioxidant, anti-inflammatory, and neuroprotective activity of LCM is an important prerequisite for its anticonvulsant and beneficial effects on SE-induced behavioral comorbidities. The results of this study indicate that treatment with SCBs might be effective and safe in a subset of patients with CDD-related epilepsy.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Racial variations in lacosamide serum concentrations in adult patients with epilepsy. (Pubmed Central) - May 15, 2021
Overall, AA patients had a weaker relationship between LCM daily dose (adjusted for weight) and serum levels as compared to White patients and require a higher LCM dose per weight to achieve similar levels. Differences in pharmacogenetics may play an important role in these findings and focus on how these variations impact seizure burden.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Lacosamide induced Brugada I morphology in the setting of septicemia: A case report. (Pubmed Central) - May 13, 2021
Various associated factors for improving adherence were identified in this study. Caution should be exercised in the use of lacosamide in those at risk for conduction delay, or in combination therapy with medications that impair renal clearance, metabolism of lacosamide, or that display inherent sodium channel blocking properties.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
PK/PD data, Review, Journal: Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. (Pubmed Central) - May 4, 2021
Herein, the pharmacology, pharmacokinetics, and clinical data of lacosamide were reviewed, giving special emphasis to the latest molecular investigations underlying its mechanism of action and therapeutic applications in pathologies other than epilepsy. In addition, the pharmacokinetic characteristics of lacosamide were updated, as well as current literature concerning the high pharmacokinetic variability observed in special patient populations that must be considered during treatment individualization.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, PK/PD data, Journal: Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. (Pubmed Central) - Apr 27, 2021
Yet, we demonstrated that measuring serum lacosamide concentrations in the critically ill population during continuous renal replacement therapy may be useful to individualize dosing programs. Further pharmacokinetic studies of lacosamide may be necessary to generate widespread dosing recommendations.
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Retrospective data, Journal: Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China. (Pubmed Central) - Apr 21, 2021
Trial completion date: Oct 2025 --> Jun 2025 | Trial primary completion date: Oct 2025 --> Jun 2025 This retrospective study of 72 pediatric patients with epilepsy in Uygur, China, showed that LCM therapy is safe and effective for epilepsy in children, resulting in a reduction in the seizure rate.
|
